| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hepatitis C, Chronic | 93 | 2020 | 1031 | 11.110 |
Why?
|
| Liver Cirrhosis | 105 | 2022 | 1957 | 10.630 |
Why?
|
| Antiviral Agents | 79 | 2022 | 3064 | 7.050 |
Why?
|
| Ribavirin | 48 | 2018 | 395 | 5.790 |
Why?
|
| Elasticity Imaging Techniques | 25 | 2024 | 395 | 5.250 |
Why?
|
| Hepacivirus | 55 | 2021 | 1341 | 4.570 |
Why?
|
| Fluorenes | 16 | 2017 | 160 | 4.240 |
Why?
|
| Uridine Monophosphate | 15 | 2017 | 67 | 3.460 |
Why?
|
| Hepatitis C | 32 | 2021 | 1593 | 3.410 |
Why?
|
| Benzimidazoles | 16 | 2017 | 864 | 3.170 |
Why?
|
| Thrombocytopenia | 14 | 2021 | 1180 | 2.470 |
Why?
|
| Liver Diseases | 13 | 2024 | 1301 | 2.260 |
Why?
|
| Hepatitis B, Chronic | 10 | 2022 | 410 | 2.230 |
Why?
|
| Interferon-alpha | 31 | 2015 | 910 | 2.010 |
Why?
|
| Liver | 52 | 2024 | 7570 | 1.860 |
Why?
|
| Alanine Transaminase | 17 | 2017 | 604 | 1.620 |
Why?
|
| Benzoates | 5 | 2014 | 213 | 1.610 |
Why?
|
| Hydrazines | 5 | 2014 | 223 | 1.600 |
Why?
|
| Fatty Liver | 14 | 2024 | 807 | 1.510 |
Why?
|
| Polyethylene Glycols | 27 | 2015 | 1195 | 1.400 |
Why?
|
| Cinnamates | 2 | 2021 | 59 | 1.370 |
Why?
|
| Receptors, Thrombopoietin | 6 | 2021 | 160 | 1.340 |
Why?
|
| Genotype | 32 | 2021 | 13038 | 1.310 |
Why?
|
| Hematologic Agents | 3 | 2014 | 39 | 1.290 |
Why?
|
| Carcinoma, Hepatocellular | 14 | 2021 | 2331 | 1.240 |
Why?
|
| Interleukins | 9 | 2012 | 795 | 1.180 |
Why?
|
| Interferons | 14 | 2017 | 717 | 1.160 |
Why?
|
| Postoperative Hemorrhage | 2 | 2021 | 418 | 1.050 |
Why?
|
| Blood Loss, Surgical | 2 | 2021 | 642 | 1.020 |
Why?
|
| Liver Neoplasms | 15 | 2021 | 4360 | 1.020 |
Why?
|
| Platelet Transfusion | 3 | 2021 | 301 | 0.980 |
Why?
|
| Liver Transplantation | 10 | 2017 | 2399 | 0.950 |
Why?
|
| Mucins | 15 | 2006 | 571 | 0.940 |
Why?
|
| Drug Therapy, Combination | 35 | 2018 | 6319 | 0.930 |
Why?
|
| Biopsy | 35 | 2021 | 6808 | 0.910 |
Why?
|
| Viral Load | 18 | 2017 | 3398 | 0.900 |
Why?
|
| Pyrazoles | 5 | 2014 | 2021 | 0.860 |
Why?
|
| Hypertension, Portal | 6 | 2021 | 230 | 0.840 |
Why?
|
| Thiazoles | 2 | 2021 | 1542 | 0.810 |
Why?
|
| Gallbladder | 14 | 2006 | 308 | 0.790 |
Why?
|
| Aspartate Aminotransferases | 11 | 2015 | 414 | 0.790 |
Why?
|
| RNA, Viral | 19 | 2018 | 2866 | 0.770 |
Why?
|
| Cholesterol | 18 | 2021 | 2912 | 0.760 |
Why?
|
| Hyaluronic Acid | 9 | 2013 | 487 | 0.720 |
Why?
|
| Proline | 4 | 2015 | 455 | 0.710 |
Why?
|
| Hepatitis B | 3 | 2022 | 707 | 0.690 |
Why?
|
| Esophageal and Gastric Varices | 3 | 2010 | 214 | 0.680 |
Why?
|
| Portal Pressure | 3 | 2021 | 62 | 0.650 |
Why?
|
| Gastric Mucins | 5 | 2009 | 19 | 0.650 |
Why?
|
| Recombinant Proteins | 33 | 2015 | 6512 | 0.640 |
Why?
|
| Drug Interactions | 2 | 2021 | 1420 | 0.630 |
Why?
|
| Cholelithiasis | 8 | 2006 | 408 | 0.630 |
Why?
|
| Middle Aged | 127 | 2024 | 223463 | 0.600 |
Why?
|
| Humans | 237 | 2024 | 768298 | 0.590 |
Why?
|
| Bile | 10 | 2005 | 299 | 0.590 |
Why?
|
| Hepatic Veins | 2 | 2019 | 112 | 0.590 |
Why?
|
| Imidazoles | 3 | 2018 | 1168 | 0.590 |
Why?
|
| Benzofurans | 1 | 2018 | 139 | 0.570 |
Why?
|
| Male | 151 | 2024 | 364870 | 0.560 |
Why?
|
| Vibration | 3 | 2015 | 335 | 0.550 |
Why?
|
| Hematinics | 5 | 2013 | 282 | 0.540 |
Why?
|
| Hepatitis B e Antigens | 6 | 2022 | 135 | 0.530 |
Why?
|
| Oligopeptides | 4 | 2015 | 1194 | 0.520 |
Why?
|
| Female | 150 | 2024 | 397050 | 0.520 |
Why?
|
| Drug Therapy | 1 | 2019 | 504 | 0.520 |
Why?
|
| Quinoxalines | 1 | 2018 | 296 | 0.520 |
Why?
|
| Adult | 107 | 2024 | 223622 | 0.510 |
Why?
|
| Silymarin | 6 | 2012 | 44 | 0.500 |
Why?
|
| End Stage Liver Disease | 4 | 2021 | 370 | 0.490 |
Why?
|
| Histocytochemistry | 3 | 2017 | 699 | 0.490 |
Why?
|
| Keratin-18 | 3 | 2016 | 37 | 0.490 |
Why?
|
| Disease Progression | 26 | 2022 | 13646 | 0.480 |
Why?
|
| Diagnostic Tests, Routine | 3 | 2014 | 790 | 0.470 |
Why?
|
| Erythropoietin | 5 | 2013 | 719 | 0.470 |
Why?
|
| Cost-Benefit Analysis | 7 | 2017 | 5538 | 0.470 |
Why?
|
| Hepatitis, Viral, Human | 3 | 2015 | 141 | 0.470 |
Why?
|
| Liver Cirrhosis, Experimental | 2 | 2008 | 30 | 0.460 |
Why?
|
| Drug Administration Schedule | 9 | 2019 | 4859 | 0.460 |
Why?
|
| Chronic Disease | 13 | 2024 | 9380 | 0.460 |
Why?
|
| Hepatic Encephalopathy | 2 | 2018 | 144 | 0.460 |
Why?
|
| Protease Inhibitors | 2 | 2015 | 752 | 0.460 |
Why?
|
| Severity of Illness Index | 24 | 2021 | 15939 | 0.450 |
Why?
|
| Nucleosides | 1 | 2014 | 131 | 0.450 |
Why?
|
| Treatment Outcome | 43 | 2022 | 65365 | 0.440 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2019 | 749 | 0.440 |
Why?
|
| Perioperative Care | 1 | 2021 | 1045 | 0.420 |
Why?
|
| Predictive Value of Tests | 17 | 2016 | 15455 | 0.410 |
Why?
|
| Hepatitis, Chronic | 2 | 2016 | 53 | 0.410 |
Why?
|
| Cystadenocarcinoma | 1 | 2012 | 54 | 0.410 |
Why?
|
| Platelet Count | 9 | 2014 | 784 | 0.400 |
Why?
|
| Nucleotides | 1 | 2014 | 455 | 0.390 |
Why?
|
| Liver Circulation | 3 | 2008 | 158 | 0.370 |
Why?
|
| Proton Pump Inhibitors | 1 | 2016 | 553 | 0.370 |
Why?
|
| Point-of-Care Systems | 2 | 2024 | 1238 | 0.370 |
Why?
|
| Biopsy, Needle | 6 | 2012 | 1627 | 0.360 |
Why?
|
| Clinical Enzyme Tests | 1 | 2010 | 114 | 0.360 |
Why?
|
| Gallstones | 4 | 2010 | 285 | 0.350 |
Why?
|
| Aged | 59 | 2021 | 171544 | 0.350 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 3 | 2009 | 150 | 0.330 |
Why?
|
| Benzazepines | 1 | 2011 | 311 | 0.330 |
Why?
|
| Fibrosis | 9 | 2024 | 2076 | 0.330 |
Why?
|
| Liver Function Tests | 7 | 2011 | 525 | 0.320 |
Why?
|
| Portasystemic Shunt, Transjugular Intrahepatic | 1 | 2010 | 96 | 0.320 |
Why?
|
| Hyponatremia | 1 | 2011 | 280 | 0.320 |
Why?
|
| ROC Curve | 12 | 2021 | 3622 | 0.320 |
Why?
|
| Basal Ganglia | 1 | 2011 | 555 | 0.310 |
Why?
|
| Carbamates | 3 | 2016 | 192 | 0.310 |
Why?
|
| Intracranial Hemorrhages | 1 | 2014 | 811 | 0.310 |
Why?
|
| Cholestasis, Intrahepatic | 3 | 2015 | 75 | 0.300 |
Why?
|
| Methylene Blue | 2 | 2007 | 156 | 0.300 |
Why?
|
| Isoindoles | 1 | 2008 | 36 | 0.300 |
Why?
|
| Dose-Response Relationship, Drug | 13 | 2019 | 10776 | 0.300 |
Why?
|
| Viral Nonstructural Proteins | 6 | 2016 | 228 | 0.300 |
Why?
|
| Anthropometry | 1 | 2012 | 1343 | 0.300 |
Why?
|
| Prognosis | 18 | 2021 | 30020 | 0.300 |
Why?
|
| Adenosine Deaminase | 2 | 2021 | 252 | 0.290 |
Why?
|
| Gastroenterology | 1 | 2014 | 589 | 0.290 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2010 | 429 | 0.290 |
Why?
|
| Anemia | 8 | 2013 | 1520 | 0.290 |
Why?
|
| Hemangioma | 1 | 2012 | 727 | 0.280 |
Why?
|
| Diagnostic Techniques, Digestive System | 1 | 2007 | 45 | 0.270 |
Why?
|
| Substance P | 1 | 2008 | 332 | 0.270 |
Why?
|
| Gastric Mucosa | 2 | 2009 | 602 | 0.270 |
Why?
|
| Sensitivity and Specificity | 15 | 2016 | 14736 | 0.260 |
Why?
|
| DNA, Viral | 4 | 2022 | 2205 | 0.260 |
Why?
|
| Administration, Oral | 7 | 2019 | 4043 | 0.260 |
Why?
|
| Health Care Costs | 3 | 2015 | 3267 | 0.260 |
Why?
|
| Confidence Intervals | 3 | 2019 | 2931 | 0.260 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 2010 | 317 | 0.260 |
Why?
|
| Double-Blind Method | 19 | 2019 | 12457 | 0.260 |
Why?
|
| Crystallization | 10 | 2010 | 523 | 0.260 |
Why?
|
| Schistosomiasis | 1 | 2006 | 65 | 0.250 |
Why?
|
| Nitric Oxide Synthase | 2 | 2007 | 911 | 0.250 |
Why?
|
| Retrospective Studies | 20 | 2022 | 81768 | 0.240 |
Why?
|
| Drug Design | 1 | 2010 | 1046 | 0.240 |
Why?
|
| Frontal Lobe | 1 | 2011 | 1428 | 0.240 |
Why?
|
| United States | 23 | 2024 | 73144 | 0.240 |
Why?
|
| Glycoproteins | 6 | 2009 | 2204 | 0.240 |
Why?
|
| Endosonography | 1 | 2009 | 622 | 0.240 |
Why?
|
| Collagen Type III | 1 | 2005 | 92 | 0.240 |
Why?
|
| Hepatitis B virus | 2 | 2022 | 527 | 0.240 |
Why?
|
| Biochemistry | 1 | 2005 | 116 | 0.240 |
Why?
|
| Drug Resistance, Viral | 5 | 2016 | 869 | 0.230 |
Why?
|
| Guanine | 2 | 2017 | 280 | 0.230 |
Why?
|
| Cohort Studies | 16 | 2024 | 41791 | 0.230 |
Why?
|
| Prospective Studies | 24 | 2024 | 54921 | 0.230 |
Why?
|
| Blood Flow Velocity | 1 | 2008 | 1375 | 0.230 |
Why?
|
| Sarcina | 1 | 2023 | 10 | 0.230 |
Why?
|
| Serum | 3 | 2017 | 207 | 0.220 |
Why?
|
| Hepatitis B Surface Antigens | 3 | 2022 | 294 | 0.220 |
Why?
|
| Adenoma | 2 | 2012 | 2163 | 0.220 |
Why?
|
| Cholangitis, Sclerosing | 2 | 2019 | 179 | 0.220 |
Why?
|
| Young Adult | 20 | 2021 | 60048 | 0.220 |
Why?
|
| Drug Combinations | 4 | 2018 | 2078 | 0.210 |
Why?
|
| Stomach | 2 | 2023 | 703 | 0.210 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2010 | 1126 | 0.210 |
Why?
|
| Microspheres | 2 | 2004 | 789 | 0.210 |
Why?
|
| Aged, 80 and over | 17 | 2023 | 59683 | 0.210 |
Why?
|
| Health Services Research | 1 | 2010 | 1817 | 0.200 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 2 | 2021 | 1658 | 0.200 |
Why?
|
| Proteomics | 2 | 2024 | 3906 | 0.200 |
Why?
|
| Sterols | 2 | 2004 | 63 | 0.200 |
Why?
|
| Benzamides | 2 | 2018 | 1380 | 0.200 |
Why?
|
| HIV Infections | 8 | 2014 | 17575 | 0.200 |
Why?
|
| Diffusion of Innovation | 1 | 2007 | 732 | 0.190 |
Why?
|
| Mass Screening | 2 | 2013 | 5451 | 0.190 |
Why?
|
| Interferon Type I | 1 | 2005 | 569 | 0.190 |
Why?
|
| Chemokine CXCL10 | 2 | 2014 | 311 | 0.190 |
Why?
|
| Kupffer Cells | 1 | 2021 | 143 | 0.190 |
Why?
|
| Bile Ducts | 2 | 2011 | 287 | 0.180 |
Why?
|
| Mitochondria, Liver | 1 | 2021 | 191 | 0.180 |
Why?
|
| Bile Duct Diseases | 1 | 2001 | 97 | 0.180 |
Why?
|
| Hepatic Stellate Cells | 2 | 2012 | 117 | 0.180 |
Why?
|
| Autocrine Communication | 1 | 2021 | 168 | 0.180 |
Why?
|
| Registries | 2 | 2016 | 8378 | 0.180 |
Why?
|
| Weight Loss | 1 | 2012 | 2715 | 0.180 |
Why?
|
| Randomized Controlled Trials as Topic | 9 | 2021 | 10377 | 0.180 |
Why?
|
| Acetyltransferases | 1 | 2021 | 231 | 0.180 |
Why?
|
| Ascites | 3 | 2018 | 338 | 0.180 |
Why?
|
| Collagen | 5 | 2022 | 2646 | 0.180 |
Why?
|
| Quantitative Trait Loci | 2 | 2010 | 2127 | 0.180 |
Why?
|
| Cattle | 10 | 2004 | 3827 | 0.170 |
Why?
|
| Hemorrhage | 1 | 2012 | 3461 | 0.170 |
Why?
|
| Quality Indicators, Health Care | 1 | 2010 | 1813 | 0.170 |
Why?
|
| Paracrine Communication | 1 | 2021 | 278 | 0.170 |
Why?
|
| Hepatitis, Alcoholic | 1 | 2021 | 110 | 0.170 |
Why?
|
| Risk Assessment | 9 | 2024 | 24316 | 0.170 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2021 | 128 | 0.170 |
Why?
|
| Quality Assurance, Health Care | 1 | 2010 | 2180 | 0.170 |
Why?
|
| Cell-Derived Microparticles | 2 | 2012 | 161 | 0.170 |
Why?
|
| Tooth Extraction | 1 | 2021 | 229 | 0.170 |
Why?
|
| Lectins | 4 | 2013 | 490 | 0.160 |
Why?
|
| Adipokines | 4 | 2013 | 309 | 0.160 |
Why?
|
| Focal Nodular Hyperplasia | 2 | 2012 | 29 | 0.160 |
Why?
|
| Clinical Trials, Phase III as Topic | 3 | 2019 | 876 | 0.150 |
Why?
|
| Endoscopy, Digestive System | 1 | 2021 | 357 | 0.150 |
Why?
|
| Desmosine | 1 | 1997 | 19 | 0.150 |
Why?
|
| MAP Kinase Kinase Kinase 5 | 1 | 2017 | 20 | 0.150 |
Why?
|
| Magnetic Resonance Imaging | 8 | 2018 | 36849 | 0.150 |
Why?
|
| Amino Acid Oxidoreductases | 1 | 2018 | 149 | 0.150 |
Why?
|
| Recurrence | 4 | 2014 | 8501 | 0.150 |
Why?
|
| Aging, Premature | 1 | 2018 | 44 | 0.150 |
Why?
|
| Adenine | 2 | 2014 | 993 | 0.150 |
Why?
|
| Neutropenia | 3 | 2011 | 893 | 0.150 |
Why?
|
| Cell Transplantation | 1 | 1999 | 474 | 0.140 |
Why?
|
| Cognition Disorders | 1 | 2011 | 3985 | 0.140 |
Why?
|
| Hepatitis B Virus, Woodchuck | 1 | 2017 | 6 | 0.140 |
Why?
|
| Procollagen | 3 | 2006 | 189 | 0.140 |
Why?
|
| Marmota | 1 | 2017 | 13 | 0.140 |
Why?
|
| Liver Diseases, Alcoholic | 2 | 2016 | 162 | 0.140 |
Why?
|
| Decision Support Techniques | 2 | 2017 | 2005 | 0.140 |
Why?
|
| Reagent Kits, Diagnostic | 2 | 2015 | 239 | 0.140 |
Why?
|
| Radiography | 3 | 2019 | 6993 | 0.140 |
Why?
|
| Practice Guidelines as Topic | 2 | 2013 | 7453 | 0.140 |
Why?
|
| Crohn Disease | 3 | 1999 | 2293 | 0.140 |
Why?
|
| Anesthesia | 1 | 2008 | 1596 | 0.140 |
Why?
|
| Time Factors | 15 | 2018 | 40267 | 0.130 |
Why?
|
| Receptors, Concanavalin A | 2 | 1993 | 11 | 0.130 |
Why?
|
| Solutions | 3 | 2005 | 409 | 0.130 |
Why?
|
| Pyridines | 2 | 2018 | 2889 | 0.130 |
Why?
|
| Epoetin Alfa | 3 | 2004 | 78 | 0.130 |
Why?
|
| Viscosity | 4 | 2009 | 336 | 0.130 |
Why?
|
| Age Factors | 6 | 2016 | 18472 | 0.130 |
Why?
|
| Sigmoidoscopy | 1 | 1996 | 151 | 0.130 |
Why?
|
| Polymorphism, Genetic | 4 | 2012 | 4250 | 0.130 |
Why?
|
| Forecasting | 2 | 2019 | 2948 | 0.130 |
Why?
|
| Enzyme Inhibitors | 3 | 2018 | 3722 | 0.120 |
Why?
|
| Concanavalin A | 2 | 1996 | 190 | 0.120 |
Why?
|
| Lipoproteins, VLDL | 1 | 2016 | 201 | 0.120 |
Why?
|
| Ammonia | 1 | 2016 | 248 | 0.120 |
Why?
|
| Cholesterol, Dietary | 2 | 2005 | 224 | 0.120 |
Why?
|
| Carbon Tetrachloride | 2 | 2008 | 72 | 0.120 |
Why?
|
| Calcium Phosphates | 1 | 1995 | 172 | 0.120 |
Why?
|
| Adolescent | 16 | 2021 | 89182 | 0.120 |
Why?
|
| RNA | 3 | 2022 | 2726 | 0.120 |
Why?
|
| Boston | 5 | 2014 | 9371 | 0.120 |
Why?
|
| Patient Care Management | 2 | 2007 | 304 | 0.120 |
Why?
|
| Serine Proteinase Inhibitors | 2 | 2013 | 174 | 0.110 |
Why?
|
| Aspirin | 2 | 2016 | 3136 | 0.110 |
Why?
|
| alpha-Fetoproteins | 3 | 2011 | 227 | 0.110 |
Why?
|
| Animals | 33 | 2017 | 169322 | 0.110 |
Why?
|
| Diagnostic Imaging | 2 | 2008 | 3541 | 0.110 |
Why?
|
| Data Interpretation, Statistical | 2 | 2018 | 2708 | 0.110 |
Why?
|
| New Zealand | 1 | 2014 | 360 | 0.110 |
Why?
|
| Reproducibility of Results | 9 | 2019 | 20224 | 0.110 |
Why?
|
| Ultrasonography, Doppler | 2 | 2007 | 463 | 0.110 |
Why?
|
| Liposomes | 1 | 1997 | 792 | 0.110 |
Why?
|
| Amino Acids | 2 | 1997 | 1716 | 0.110 |
Why?
|
| Aminopeptidases | 1 | 1994 | 114 | 0.110 |
Why?
|
| Waiting Lists | 2 | 2017 | 780 | 0.110 |
Why?
|
| Blood Chemical Analysis | 1 | 2015 | 436 | 0.110 |
Why?
|
| Alprostadil | 1 | 1993 | 86 | 0.110 |
Why?
|
| Quality-Adjusted Life Years | 2 | 2017 | 1735 | 0.110 |
Why?
|
| Pyrophosphatases | 2 | 2011 | 142 | 0.110 |
Why?
|
| Monocytes | 2 | 2021 | 2594 | 0.110 |
Why?
|
| Follow-Up Studies | 12 | 2018 | 39405 | 0.110 |
Why?
|
| Bilirubin | 3 | 2009 | 438 | 0.110 |
Why?
|
| Cryptosporidiosis | 1 | 1993 | 52 | 0.100 |
Why?
|
| Hydrogen-Ion Concentration | 5 | 2009 | 2487 | 0.100 |
Why?
|
| Models, Economic | 1 | 2017 | 718 | 0.100 |
Why?
|
| Lamivudine | 1 | 2014 | 367 | 0.100 |
Why?
|
| Transforming Growth Factor beta | 3 | 2012 | 2003 | 0.100 |
Why?
|
| Liver Abscess, Pyogenic | 1 | 2012 | 7 | 0.100 |
Why?
|
| Liver Abscess, Amebic | 1 | 2012 | 19 | 0.100 |
Why?
|
| Swine | 7 | 2009 | 5993 | 0.100 |
Why?
|
| alpha-Macroglobulins | 2 | 2009 | 60 | 0.100 |
Why?
|
| Echinococcosis | 1 | 2012 | 32 | 0.100 |
Why?
|
| Intention to Treat Analysis | 1 | 2013 | 417 | 0.100 |
Why?
|
| Polymorphism, Single Nucleotide | 5 | 2012 | 16027 | 0.100 |
Why?
|
| Cholangitis | 1 | 1993 | 110 | 0.100 |
Why?
|
| Muscle Contraction | 1 | 1997 | 1208 | 0.100 |
Why?
|
| Quality of Life | 6 | 2015 | 13499 | 0.100 |
Why?
|
| Nucleotidyltransferases | 1 | 2014 | 243 | 0.100 |
Why?
|
| Interferon-gamma | 4 | 2012 | 3164 | 0.100 |
Why?
|
| Professional Practice | 1 | 2014 | 314 | 0.100 |
Why?
|
| Receptors, Natural Killer Cell | 1 | 2011 | 56 | 0.100 |
Why?
|
| Reference Values | 1 | 2019 | 4941 | 0.100 |
Why?
|
| Europe | 2 | 2018 | 3439 | 0.100 |
Why?
|
| Prevalence | 6 | 2021 | 15868 | 0.090 |
Why?
|
| Scattering, Radiation | 3 | 1999 | 489 | 0.090 |
Why?
|
| Cholestasis | 1 | 2014 | 383 | 0.090 |
Why?
|
| Image Processing, Computer-Assisted | 3 | 2021 | 9063 | 0.090 |
Why?
|
| Elasticity | 3 | 2009 | 657 | 0.090 |
Why?
|
| Thrombopoiesis | 1 | 2013 | 166 | 0.090 |
Why?
|
| Clofazimine | 1 | 1991 | 41 | 0.090 |
Why?
|
| Hemoglobins | 5 | 2013 | 1532 | 0.090 |
Why?
|
| Sex Factors | 3 | 2016 | 10656 | 0.090 |
Why?
|
| Calcium-Binding Proteins | 1 | 1995 | 1084 | 0.090 |
Why?
|
| Inositol | 1 | 2011 | 216 | 0.090 |
Why?
|
| Cross-Sectional Studies | 7 | 2024 | 26373 | 0.090 |
Why?
|
| Leukopenia | 1 | 2011 | 212 | 0.090 |
Why?
|
| Postoperative Care | 1 | 2017 | 1479 | 0.090 |
Why?
|
| Extracellular Matrix | 3 | 2003 | 1739 | 0.090 |
Why?
|
| Drug Users | 1 | 2012 | 134 | 0.090 |
Why?
|
| Software | 1 | 2024 | 4452 | 0.090 |
Why?
|
| Antigens, Neoplasm | 3 | 2006 | 1999 | 0.090 |
Why?
|
| Macromolecular Substances | 2 | 2005 | 1435 | 0.090 |
Why?
|
| Cerebrovascular Disorders | 1 | 2017 | 1486 | 0.090 |
Why?
|
| Withholding Treatment | 1 | 2014 | 620 | 0.090 |
Why?
|
| Multivariate Analysis | 7 | 2016 | 12092 | 0.080 |
Why?
|
| Injections, Subcutaneous | 3 | 2018 | 687 | 0.080 |
Why?
|
| Lipase | 1 | 2012 | 321 | 0.080 |
Why?
|
| Clinical Trials, Phase II as Topic | 3 | 2021 | 640 | 0.080 |
Why?
|
| Biophysical Phenomena | 3 | 2002 | 321 | 0.080 |
Why?
|
| Choline | 1 | 2011 | 518 | 0.080 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2010 | 169 | 0.080 |
Why?
|
| Phytotherapy | 1 | 2011 | 298 | 0.080 |
Why?
|
| Creatine | 1 | 2011 | 427 | 0.080 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2012 | 622 | 0.080 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 1993 | 664 | 0.080 |
Why?
|
| Colon | 3 | 2005 | 1805 | 0.080 |
Why?
|
| Polytetrafluoroethylene | 1 | 2010 | 245 | 0.080 |
Why?
|
| Biophysics | 3 | 2002 | 379 | 0.080 |
Why?
|
| Physicians, Primary Care | 1 | 2016 | 623 | 0.080 |
Why?
|
| Anemia, Hemolytic | 1 | 2010 | 164 | 0.080 |
Why?
|
| Aspartic Acid | 1 | 2011 | 577 | 0.080 |
Why?
|
| Peptide Fragments | 5 | 2006 | 5151 | 0.080 |
Why?
|
| Killer Cells, Natural | 2 | 2011 | 2207 | 0.080 |
Why?
|
| Hepatitis C Antibodies | 1 | 2009 | 151 | 0.080 |
Why?
|
| gamma-Glutamyltransferase | 1 | 2009 | 144 | 0.080 |
Why?
|
| Molecular Weight | 2 | 2005 | 2172 | 0.080 |
Why?
|
| Uncertainty | 1 | 2013 | 759 | 0.080 |
Why?
|
| Patient Admission | 1 | 2016 | 1367 | 0.080 |
Why?
|
| Head | 1 | 2014 | 927 | 0.080 |
Why?
|
| Cystatins | 1 | 2008 | 55 | 0.070 |
Why?
|
| Algorithms | 4 | 2024 | 14154 | 0.070 |
Why?
|
| Nitric Oxide | 1 | 1997 | 2143 | 0.070 |
Why?
|
| Preoperative Care | 1 | 2017 | 2257 | 0.070 |
Why?
|
| Intestinal Absorption | 2 | 2004 | 400 | 0.070 |
Why?
|
| Immunologic Factors | 1 | 2017 | 1598 | 0.070 |
Why?
|
| Pentanoic Acids | 1 | 2007 | 19 | 0.070 |
Why?
|
| Area Under Curve | 4 | 2015 | 1642 | 0.070 |
Why?
|
| Publishing | 1 | 2015 | 836 | 0.070 |
Why?
|
| Mucus | 1 | 2009 | 346 | 0.070 |
Why?
|
| Patient Compliance | 3 | 2013 | 2693 | 0.070 |
Why?
|
| Hyperlipidemias | 1 | 2012 | 773 | 0.070 |
Why?
|
| Splenic Artery | 1 | 2007 | 57 | 0.070 |
Why?
|
| Surgical Procedures, Operative | 1 | 2019 | 1937 | 0.070 |
Why?
|
| Fluorescent Dyes | 4 | 1999 | 1926 | 0.070 |
Why?
|
| Triglycerides | 1 | 2015 | 2465 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2014 | 20766 | 0.070 |
Why?
|
| Hypereosinophilic Syndrome | 1 | 2008 | 97 | 0.070 |
Why?
|
| Phase Transition | 1 | 2007 | 70 | 0.070 |
Why?
|
| Intestinal Polyps | 1 | 1987 | 105 | 0.070 |
Why?
|
| Risk | 1 | 2019 | 9635 | 0.070 |
Why?
|
| Acute Disease | 3 | 2006 | 7242 | 0.070 |
Why?
|
| Dietary Supplements | 2 | 2011 | 3443 | 0.070 |
Why?
|
| Cysts | 1 | 2012 | 685 | 0.070 |
Why?
|
| Colonic Diseases, Functional | 1 | 1986 | 39 | 0.070 |
Why?
|
| Immunohistochemistry | 5 | 2012 | 11117 | 0.070 |
Why?
|
| Pharmacogenetics | 1 | 2011 | 683 | 0.070 |
Why?
|
| Clinical Trials as Topic | 4 | 2012 | 8051 | 0.070 |
Why?
|
| Treatment Failure | 4 | 2016 | 2664 | 0.070 |
Why?
|
| Phenylurea Compounds | 1 | 2009 | 529 | 0.070 |
Why?
|
| Risk Factors | 9 | 2022 | 74954 | 0.070 |
Why?
|
| Spectrometry, Fluorescence | 2 | 2004 | 694 | 0.070 |
Why?
|
| Cystatin C | 1 | 2008 | 272 | 0.070 |
Why?
|
| Renal Circulation | 1 | 2007 | 291 | 0.070 |
Why?
|
| Hepatic Artery | 1 | 2007 | 232 | 0.070 |
Why?
|
| Diffusion | 2 | 1999 | 818 | 0.070 |
Why?
|
| Sodium | 1 | 2011 | 1594 | 0.070 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 2007 | 706 | 0.070 |
Why?
|
| Microscopy, Fluorescence | 3 | 2009 | 2636 | 0.070 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2008 | 504 | 0.060 |
Why?
|
| Ubiquitin | 1 | 2011 | 843 | 0.060 |
Why?
|
| Serologic Tests | 1 | 2008 | 383 | 0.060 |
Why?
|
| Thrombopoietin | 1 | 2008 | 226 | 0.060 |
Why?
|
| Helicobacter pylori | 1 | 2009 | 381 | 0.060 |
Why?
|
| Peptides | 3 | 1999 | 4352 | 0.060 |
Why?
|
| Prednisone | 2 | 2008 | 1568 | 0.060 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2016 | 2277 | 0.060 |
Why?
|
| Vascular Resistance | 2 | 2007 | 940 | 0.060 |
Why?
|
| Renin-Angiotensin System | 1 | 2010 | 739 | 0.060 |
Why?
|
| Socioeconomic Factors | 1 | 2019 | 7861 | 0.060 |
Why?
|
| Phlebitis | 1 | 2005 | 35 | 0.060 |
Why?
|
| Sciuridae | 2 | 1997 | 79 | 0.060 |
Why?
|
| Carbohydrate Metabolism | 1 | 1986 | 262 | 0.060 |
Why?
|
| Combined Modality Therapy | 1 | 2017 | 8562 | 0.060 |
Why?
|
| Microscopy, Atomic Force | 1 | 2005 | 251 | 0.060 |
Why?
|
| Transaminases | 1 | 2005 | 199 | 0.060 |
Why?
|
| Fibrinolysis | 2 | 2001 | 331 | 0.060 |
Why?
|
| Docosahexaenoic Acids | 1 | 2011 | 907 | 0.060 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2024 | 3811 | 0.060 |
Why?
|
| Insulin Resistance | 2 | 2010 | 3981 | 0.060 |
Why?
|
| Protein Conformation | 2 | 2005 | 3957 | 0.060 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 3 | 1993 | 1732 | 0.060 |
Why?
|
| MicroRNAs | 2 | 2011 | 3794 | 0.060 |
Why?
|
| T-Lymphocytes, Cytotoxic | 3 | 1998 | 1795 | 0.060 |
Why?
|
| Ileal Neoplasms | 1 | 1984 | 20 | 0.060 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2011 | 1320 | 0.060 |
Why?
|
| Estrogen Receptor alpha | 2 | 2005 | 580 | 0.060 |
Why?
|
| Cholesterol 7-alpha-Hydroxylase | 1 | 2004 | 28 | 0.060 |
Why?
|
| Molecular Conformation | 1 | 2005 | 540 | 0.060 |
Why?
|
| Substance Abuse, Intravenous | 2 | 2006 | 530 | 0.060 |
Why?
|
| Cardiac Output | 1 | 2007 | 838 | 0.060 |
Why?
|
| Diagnosis, Differential | 4 | 2021 | 13019 | 0.060 |
Why?
|
| Blood Coagulation Disorders | 1 | 2007 | 350 | 0.060 |
Why?
|
| Antioxidants | 1 | 2012 | 1673 | 0.060 |
Why?
|
| CD8-Positive T-Lymphocytes | 3 | 2012 | 4647 | 0.060 |
Why?
|
| Epigenesis, Genetic | 1 | 2018 | 3826 | 0.060 |
Why?
|
| Integrin alpha1beta1 | 1 | 2003 | 8 | 0.060 |
Why?
|
| Integrin alpha2beta1 | 1 | 2003 | 17 | 0.060 |
Why?
|
| RNA, Messenger | 5 | 2006 | 12801 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-sis | 2 | 2021 | 254 | 0.060 |
Why?
|
| Protective Agents | 1 | 2005 | 150 | 0.060 |
Why?
|
| Growth Substances | 2 | 2003 | 761 | 0.060 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2010 | 887 | 0.060 |
Why?
|
| Iron Overload | 1 | 2006 | 246 | 0.060 |
Why?
|
| Neurotransmitter Agents | 1 | 2008 | 665 | 0.060 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2018 | 2295 | 0.060 |
Why?
|
| Drug Implants | 1 | 2004 | 230 | 0.060 |
Why?
|
| Anilino Naphthalenesulfonates | 2 | 1995 | 16 | 0.060 |
Why?
|
| Interferon-beta | 1 | 2006 | 349 | 0.060 |
Why?
|
| Pilot Projects | 2 | 2014 | 8730 | 0.060 |
Why?
|
| Risk Reduction Behavior | 1 | 2010 | 1119 | 0.060 |
Why?
|
| Periodicals as Topic | 1 | 2015 | 1469 | 0.050 |
Why?
|
| DNA Methylation | 1 | 2018 | 4419 | 0.050 |
Why?
|
| Clostridium | 1 | 2023 | 101 | 0.050 |
Why?
|
| Blotting, Western | 4 | 2006 | 5033 | 0.050 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2011 | 3781 | 0.050 |
Why?
|
| Microscopy, Electron | 2 | 1997 | 2559 | 0.050 |
Why?
|
| Bradycardia | 1 | 1985 | 305 | 0.050 |
Why?
|
| Gels | 2 | 2007 | 421 | 0.050 |
Why?
|
| Viral Core Proteins | 2 | 2012 | 157 | 0.050 |
Why?
|
| Mucin-1 | 2 | 2006 | 538 | 0.050 |
Why?
|
| Mental Disorders | 2 | 2017 | 6876 | 0.050 |
Why?
|
| Membrane Proteins | 4 | 2012 | 7885 | 0.050 |
Why?
|
| Ultrasonography | 2 | 2015 | 6001 | 0.050 |
Why?
|
| Macrophages | 1 | 2017 | 5796 | 0.050 |
Why?
|
| Fluoresceins | 2 | 2009 | 235 | 0.050 |
Why?
|
| Glycosylation | 1 | 2005 | 1100 | 0.050 |
Why?
|
| Alkaline Phosphatase | 2 | 2019 | 864 | 0.050 |
Why?
|
| Body Weight | 2 | 2010 | 4630 | 0.050 |
Why?
|
| Cholesterol, LDL | 1 | 2012 | 2398 | 0.050 |
Why?
|
| Sphingomyelins | 1 | 2002 | 105 | 0.050 |
Why?
|
| United States Food and Drug Administration | 1 | 2011 | 1672 | 0.050 |
Why?
|
| Light | 2 | 1999 | 1354 | 0.050 |
Why?
|
| Matrix Metalloproteinases | 2 | 2003 | 393 | 0.050 |
Why?
|
| Infusions, Intravenous | 1 | 2007 | 2226 | 0.050 |
Why?
|
| Cytokines | 4 | 2007 | 7443 | 0.050 |
Why?
|
| Immunity, Innate | 1 | 2014 | 3079 | 0.050 |
Why?
|
| Evaluation Studies as Topic | 1 | 2004 | 1629 | 0.050 |
Why?
|
| Amino Acid Sequence | 9 | 1999 | 13425 | 0.050 |
Why?
|
| Logistic Models | 4 | 2013 | 13323 | 0.050 |
Why?
|
| Serum Albumin | 1 | 2005 | 676 | 0.050 |
Why?
|
| Antigens, CD1 | 1 | 2004 | 434 | 0.050 |
Why?
|
| Energy Intake | 1 | 1989 | 2145 | 0.050 |
Why?
|
| Abdominal Pain | 2 | 2005 | 1070 | 0.050 |
Why?
|
| Health Surveys | 1 | 2011 | 4056 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2010 | 18047 | 0.050 |
Why?
|
| Mice, Inbred Strains | 1 | 2004 | 1769 | 0.050 |
Why?
|
| Electroencephalography | 1 | 2017 | 6317 | 0.050 |
Why?
|
| Actins | 2 | 2019 | 2059 | 0.050 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2017 | 5707 | 0.050 |
Why?
|
| Analgesics | 1 | 2008 | 1070 | 0.050 |
Why?
|
| Georgia (Republic) | 1 | 2020 | 39 | 0.050 |
Why?
|
| Myocardial Infarction | 1 | 2022 | 11515 | 0.050 |
Why?
|
| Neoplasm Staging | 1 | 2015 | 11254 | 0.050 |
Why?
|
| Long-Term Care | 1 | 2005 | 632 | 0.040 |
Why?
|
| Lipoproteins | 2 | 2021 | 880 | 0.040 |
Why?
|
| Collagen Type IV | 1 | 2001 | 125 | 0.040 |
Why?
|
| Estradiol | 2 | 2005 | 1952 | 0.040 |
Why?
|
| Adjuvants, Immunologic | 1 | 2006 | 998 | 0.040 |
Why?
|
| Chromosome Mapping | 2 | 2010 | 4622 | 0.040 |
Why?
|
| Georgia | 1 | 2020 | 186 | 0.040 |
Why?
|
| Gene Expression | 3 | 2012 | 7595 | 0.040 |
Why?
|
| HIV | 1 | 2007 | 1596 | 0.040 |
Why?
|
| Intestinal Obstruction | 1 | 1984 | 434 | 0.040 |
Why?
|
| CD4-Positive T-Lymphocytes | 3 | 2012 | 4411 | 0.040 |
Why?
|
| Inflammation | 2 | 2012 | 10863 | 0.040 |
Why?
|
| Apolipoproteins B | 1 | 2021 | 386 | 0.040 |
Why?
|
| North America | 2 | 2018 | 1290 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2012 | 9681 | 0.040 |
Why?
|
| Osmolar Concentration | 2 | 2007 | 657 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2004 | 1760 | 0.040 |
Why?
|
| Venous Pressure | 1 | 2019 | 54 | 0.040 |
Why?
|
| Rats | 3 | 2008 | 23833 | 0.040 |
Why?
|
| Disease Models, Animal | 3 | 2010 | 18358 | 0.040 |
Why?
|
| Protein Binding | 3 | 2005 | 9346 | 0.040 |
Why?
|
| Patient Selection | 2 | 2018 | 4265 | 0.040 |
Why?
|
| Laminin | 1 | 2001 | 406 | 0.040 |
Why?
|
| Alanine | 1 | 2022 | 613 | 0.040 |
Why?
|
| Blood Proteins | 1 | 2024 | 1186 | 0.040 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2012 | 3111 | 0.040 |
Why?
|
| Catheter Ablation | 1 | 2012 | 2776 | 0.040 |
Why?
|
| Phospholipids | 1 | 2002 | 783 | 0.040 |
Why?
|
| Neuropsychological Tests | 1 | 2011 | 7145 | 0.040 |
Why?
|
| Body Mass Index | 3 | 2015 | 13050 | 0.040 |
Why?
|
| Communicable Disease Control | 1 | 2005 | 857 | 0.040 |
Why?
|
| Static Electricity | 1 | 1999 | 261 | 0.040 |
Why?
|
| Membrane Transport Proteins | 1 | 2004 | 1034 | 0.040 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2013 | 4047 | 0.040 |
Why?
|
| Genetic Association Studies | 2 | 2021 | 2741 | 0.040 |
Why?
|
| Rectal Neoplasms | 1 | 1987 | 1185 | 0.040 |
Why?
|
| Nutrition Surveys | 2 | 2016 | 1736 | 0.040 |
Why?
|
| Rats, Inbred Lew | 1 | 1999 | 1165 | 0.040 |
Why?
|
| Angina, Unstable | 1 | 2022 | 893 | 0.040 |
Why?
|
| Bethanechol | 1 | 1997 | 12 | 0.040 |
Why?
|
| Heart Failure | 1 | 2022 | 11860 | 0.040 |
Why?
|
| Polystyrenes | 1 | 1997 | 105 | 0.040 |
Why?
|
| Diagnostic Techniques and Procedures | 1 | 2019 | 219 | 0.040 |
Why?
|
| Blood Platelets | 1 | 2008 | 2476 | 0.040 |
Why?
|
| Acrylic Resins | 1 | 1997 | 135 | 0.040 |
Why?
|
| Rheology | 2 | 2009 | 348 | 0.030 |
Why?
|
| Muscle Tonus | 1 | 1997 | 82 | 0.030 |
Why?
|
| Survival Analysis | 2 | 2012 | 10117 | 0.030 |
Why?
|
| Sigmoidoscopes | 1 | 1996 | 5 | 0.030 |
Why?
|
| Albumins | 1 | 1999 | 577 | 0.030 |
Why?
|
| Lipoprotein(a) | 1 | 2021 | 490 | 0.030 |
Why?
|
| Cholecystokinin | 1 | 1997 | 115 | 0.030 |
Why?
|
| Pronase | 1 | 1996 | 28 | 0.030 |
Why?
|
| NG-Nitroarginine Methyl Ester | 1 | 1997 | 262 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2008 | 8198 | 0.030 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 1990 | 1539 | 0.030 |
Why?
|
| Sleep Apnea Syndromes | 1 | 1985 | 982 | 0.030 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2001 | 835 | 0.030 |
Why?
|
| Molecular Sequence Data | 8 | 1999 | 17626 | 0.030 |
Why?
|
| Cytotoxicity, Immunologic | 2 | 1998 | 1355 | 0.030 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2005 | 1903 | 0.030 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2006 | 2846 | 0.030 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2004 | 1813 | 0.030 |
Why?
|
| Epithelial Cells | 2 | 2006 | 3692 | 0.030 |
Why?
|
| Interleukin-10 | 3 | 2012 | 1184 | 0.030 |
Why?
|
| Ampulla of Vater | 1 | 1996 | 150 | 0.030 |
Why?
|
| Fatty Acids | 1 | 2004 | 1817 | 0.030 |
Why?
|
| Exanthema | 2 | 2011 | 503 | 0.030 |
Why?
|
| Egypt | 2 | 2007 | 100 | 0.030 |
Why?
|
| Receptors, Estrogen | 1 | 2004 | 2247 | 0.030 |
Why?
|
| Chemical Precipitation | 1 | 1995 | 175 | 0.030 |
Why?
|
| Nephelometry and Turbidimetry | 1 | 1995 | 91 | 0.030 |
Why?
|
| Lipids | 2 | 2004 | 3344 | 0.030 |
Why?
|
| Endometriosis | 1 | 1984 | 875 | 0.030 |
Why?
|
| In Situ Hybridization | 1 | 1999 | 1905 | 0.030 |
Why?
|
| Energy Transfer | 1 | 1995 | 109 | 0.030 |
Why?
|
| Genes, Viral | 1 | 2016 | 655 | 0.030 |
Why?
|
| Exercise | 1 | 2012 | 5947 | 0.030 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2004 | 2202 | 0.030 |
Why?
|
| Receptors, Lipoprotein | 1 | 1995 | 88 | 0.030 |
Why?
|
| Proteins | 1 | 1990 | 6006 | 0.030 |
Why?
|
| Conserved Sequence | 1 | 1998 | 1163 | 0.030 |
Why?
|
| Species Specificity | 1 | 1999 | 2417 | 0.030 |
Why?
|
| Colonic Neoplasms | 1 | 1987 | 2542 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2013 | 5375 | 0.030 |
Why?
|
| Lipid Metabolism | 2 | 2004 | 1900 | 0.030 |
Why?
|
| Physicians | 1 | 2013 | 4614 | 0.030 |
Why?
|
| Estrogen Antagonists | 2 | 2005 | 150 | 0.030 |
Why?
|
| Fiber Optic Technology | 1 | 1996 | 291 | 0.030 |
Why?
|
| Up-Regulation | 2 | 2016 | 4137 | 0.030 |
Why?
|
| Phlebotomy | 1 | 2015 | 138 | 0.030 |
Why?
|
| Immunochemistry | 1 | 1994 | 116 | 0.030 |
Why?
|
| Chromatography, Gel | 2 | 1996 | 638 | 0.030 |
Why?
|
| Remission Induction | 2 | 1991 | 2407 | 0.030 |
Why?
|
| Binding, Competitive | 1 | 1995 | 1142 | 0.030 |
Why?
|
| Cysteine | 2 | 1997 | 895 | 0.030 |
Why?
|
| Decision Trees | 1 | 2016 | 509 | 0.030 |
Why?
|
| Linear Models | 2 | 2016 | 5878 | 0.030 |
Why?
|
| Cognition | 1 | 2011 | 7074 | 0.030 |
Why?
|
| Depression | 1 | 2013 | 8241 | 0.030 |
Why?
|
| Spleen | 1 | 1999 | 2295 | 0.030 |
Why?
|
| Crystallography | 1 | 1993 | 111 | 0.030 |
Why?
|
| Transforming Growth Factor beta1 | 2 | 2010 | 637 | 0.030 |
Why?
|
| Particle Size | 1 | 1997 | 1653 | 0.030 |
Why?
|
| CpG Islands | 1 | 2018 | 1208 | 0.030 |
Why?
|
| Probability | 1 | 2018 | 2482 | 0.030 |
Why?
|
| Mice | 8 | 2010 | 82004 | 0.030 |
Why?
|
| Headache | 2 | 2013 | 1262 | 0.030 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2012 | 146 | 0.030 |
Why?
|
| Blood Pressure | 2 | 2007 | 8541 | 0.030 |
Why?
|
| Portal System | 1 | 1992 | 49 | 0.020 |
Why?
|
| Hypertension | 1 | 2012 | 8615 | 0.020 |
Why?
|
| Metaplasia | 1 | 1993 | 326 | 0.020 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2005 | 4076 | 0.020 |
Why?
|
| Receptors, KIR2DL1 | 1 | 2011 | 13 | 0.020 |
Why?
|
| Receptors, KIR2DL3 | 1 | 2011 | 15 | 0.020 |
Why?
|
| Receptors, KIR3DL1 | 1 | 2011 | 27 | 0.020 |
Why?
|
| Puerto Rico | 1 | 2013 | 380 | 0.020 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily C | 1 | 2011 | 38 | 0.020 |
Why?
|
| Catheterization | 1 | 1996 | 1431 | 0.020 |
Why?
|
| Colonic Polyps | 1 | 1996 | 557 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 1999 | 2394 | 0.020 |
Why?
|
| Apoptosis | 1 | 2007 | 9506 | 0.020 |
Why?
|
| Water | 1 | 1997 | 1418 | 0.020 |
Why?
|
| Proportional Hazards Models | 2 | 2016 | 12557 | 0.020 |
Why?
|
| Receptor, Interferon alpha-beta | 1 | 2011 | 114 | 0.020 |
Why?
|
| Plasma | 1 | 2014 | 585 | 0.020 |
Why?
|
| Mass Spectrometry | 1 | 2018 | 2201 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2011 | 4584 | 0.020 |
Why?
|
| Organ Culture Techniques | 1 | 1993 | 796 | 0.020 |
Why?
|
| Prothrombin | 1 | 2011 | 193 | 0.020 |
Why?
|
| Multiple Sclerosis | 1 | 2006 | 3247 | 0.020 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2017 | 1955 | 0.020 |
Why?
|
| Costs and Cost Analysis | 1 | 1996 | 1669 | 0.020 |
Why?
|
| Immunologic Techniques | 1 | 1990 | 213 | 0.020 |
Why?
|
| Half-Life | 1 | 2011 | 650 | 0.020 |
Why?
|
| Sodium Dodecyl Sulfate | 1 | 1990 | 124 | 0.020 |
Why?
|
| Chromatography, Ion Exchange | 1 | 1990 | 293 | 0.020 |
Why?
|
| Binding Sites | 1 | 1999 | 6018 | 0.020 |
Why?
|
| Gastric Juice | 1 | 1989 | 59 | 0.020 |
Why?
|
| Editorial Policies | 1 | 2015 | 459 | 0.020 |
Why?
|
| Viral Envelope Proteins | 1 | 1993 | 641 | 0.020 |
Why?
|
| Nausea | 1 | 2013 | 682 | 0.020 |
Why?
|
| Obesity | 1 | 2012 | 13082 | 0.020 |
Why?
|
| Trypsin | 1 | 1990 | 491 | 0.020 |
Why?
|
| Urease | 1 | 2009 | 43 | 0.020 |
Why?
|
| Signal Transduction | 2 | 2010 | 23629 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2016 | 3438 | 0.020 |
Why?
|
| Pregnancy Complications | 1 | 2004 | 2971 | 0.020 |
Why?
|
| Drug Evaluation | 1 | 1991 | 642 | 0.020 |
Why?
|
| Antigens, Tumor-Associated, Carbohydrate | 2 | 1987 | 138 | 0.020 |
Why?
|
| Research Design | 2 | 2018 | 6209 | 0.020 |
Why?
|
| Collagen Type I | 1 | 2012 | 620 | 0.020 |
Why?
|
| Receptors, Immunologic | 1 | 1995 | 1416 | 0.020 |
Why?
|
| Jurkat Cells | 1 | 2010 | 738 | 0.020 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 1995 | 1362 | 0.020 |
Why?
|
| Viremia | 1 | 2012 | 725 | 0.020 |
Why?
|
| Transcription Factors | 2 | 2010 | 12166 | 0.020 |
Why?
|
| Virus Replication | 1 | 2017 | 2458 | 0.020 |
Why?
|
| Fasting | 1 | 2015 | 1610 | 0.020 |
Why?
|
| Models, Molecular | 1 | 1999 | 5408 | 0.020 |
Why?
|
| Peptic Ulcer Perforation | 1 | 1988 | 23 | 0.020 |
Why?
|
| Placebos | 1 | 2013 | 1668 | 0.020 |
Why?
|
| Retreatment | 1 | 2010 | 600 | 0.020 |
Why?
|
| Duodenal Ulcer | 1 | 1988 | 121 | 0.020 |
Why?
|
| Jaundice, Obstructive | 1 | 2008 | 22 | 0.020 |
Why?
|
| Genome-Wide Association Study | 2 | 2021 | 12775 | 0.020 |
Why?
|
| Hepatitis B Antibodies | 1 | 1988 | 155 | 0.020 |
Why?
|
| Immunoassay | 1 | 2011 | 744 | 0.020 |
Why?
|
| Case-Control Studies | 2 | 2018 | 22292 | 0.020 |
Why?
|
| Mucin-5B | 2 | 1998 | 148 | 0.020 |
Why?
|
| Peptide Hydrolases | 1 | 1990 | 610 | 0.020 |
Why?
|
| Epitopes | 1 | 1993 | 2525 | 0.020 |
Why?
|
| Urea | 1 | 2009 | 446 | 0.020 |
Why?
|
| Safety Management | 1 | 2012 | 765 | 0.020 |
Why?
|
| Gallbladder Emptying | 1 | 2006 | 14 | 0.020 |
Why?
|
| California | 1 | 2011 | 1443 | 0.020 |
Why?
|
| Protein Precursors | 1 | 2011 | 1134 | 0.020 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2010 | 1133 | 0.020 |
Why?
|
| Secondary Prevention | 1 | 2013 | 1476 | 0.020 |
Why?
|
| Lactulose | 1 | 1986 | 32 | 0.020 |
Why?
|
| Base Sequence | 4 | 1999 | 12421 | 0.020 |
Why?
|
| Toll-Like Receptor 9 | 1 | 2007 | 199 | 0.020 |
Why?
|
| Glycolysis | 1 | 1990 | 838 | 0.020 |
Why?
|
| Perception | 1 | 2013 | 1206 | 0.020 |
Why?
|
| International Cooperation | 1 | 2013 | 1438 | 0.020 |
Why?
|
| Genetic Variation | 1 | 2021 | 6606 | 0.020 |
Why?
|
| Information Dissemination | 1 | 2015 | 1137 | 0.020 |
Why?
|
| Linkage Disequilibrium | 1 | 2011 | 1998 | 0.020 |
Why?
|
| Estrogen Receptor Modulators | 1 | 2005 | 58 | 0.020 |
Why?
|
| Sterol Regulatory Element Binding Protein 2 | 1 | 2005 | 58 | 0.020 |
Why?
|
| Hydrogen | 1 | 1986 | 171 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2016 | 6856 | 0.020 |
Why?
|
| Outpatients | 1 | 2013 | 1603 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 2010 | 1727 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 6541 | 0.020 |
Why?
|
| Eating | 1 | 1992 | 1541 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 1996 | 5311 | 0.020 |
Why?
|
| Breath Tests | 1 | 1986 | 300 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2009 | 12239 | 0.010 |
Why?
|
| Computer Simulation | 1 | 2018 | 6277 | 0.010 |
Why?
|
| DNA, Complementary | 2 | 1998 | 1992 | 0.010 |
Why?
|
| Castration | 1 | 2004 | 150 | 0.010 |
Why?
|
| Fatty Acid Transport Proteins | 1 | 2004 | 31 | 0.010 |
Why?
|
| Cell Movement | 3 | 2003 | 5214 | 0.010 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily B | 1 | 2004 | 85 | 0.010 |
Why?
|
| Riboflavin Deficiency | 1 | 1983 | 3 | 0.010 |
Why?
|
| Vitamin B 6 Deficiency | 1 | 1983 | 18 | 0.010 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2016 | 3666 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 1987 | 1705 | 0.010 |
Why?
|
| Ascorbic Acid Deficiency | 1 | 1983 | 26 | 0.010 |
Why?
|
| Hospitals, Pediatric | 1 | 2013 | 1876 | 0.010 |
Why?
|
| Data Collection | 1 | 2013 | 3324 | 0.010 |
Why?
|
| Antigens, CD1d | 1 | 2004 | 225 | 0.010 |
Why?
|
| Mice, Transgenic | 2 | 2006 | 9563 | 0.010 |
Why?
|
| Ovariectomy | 1 | 2005 | 615 | 0.010 |
Why?
|
| Estrogen Receptor beta | 1 | 2004 | 171 | 0.010 |
Why?
|
| Thiamine Deficiency | 1 | 1983 | 48 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2010 | 2937 | 0.010 |
Why?
|
| Gastrointestinal Transit | 1 | 2004 | 101 | 0.010 |
Why?
|
| 1,2-Dipalmitoylphosphatidylcholine | 1 | 2002 | 40 | 0.010 |
Why?
|
| Referral and Consultation | 1 | 2016 | 3627 | 0.010 |
Why?
|
| Cell Line | 3 | 2004 | 15593 | 0.010 |
Why?
|
| Enterocytes | 1 | 2004 | 220 | 0.010 |
Why?
|
| Disease Management | 1 | 2013 | 2536 | 0.010 |
Why?
|
| Molecular Biology | 1 | 2006 | 573 | 0.010 |
Why?
|
| Integrin alpha Chains | 1 | 2003 | 93 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2012 | 6350 | 0.010 |
Why?
|
| Clone Cells | 2 | 1998 | 1671 | 0.010 |
Why?
|
| Chemotactic Factors | 1 | 2003 | 197 | 0.010 |
Why?
|
| Incidence | 2 | 2013 | 21544 | 0.010 |
Why?
|
| Rectum | 1 | 1987 | 900 | 0.010 |
Why?
|
| Gastrointestinal Motility | 1 | 2004 | 236 | 0.010 |
Why?
|
| Hydrogen Bonding | 1 | 2002 | 290 | 0.010 |
Why?
|
| Interleukin-13 | 1 | 2004 | 391 | 0.010 |
Why?
|
| Models, Immunological | 1 | 2004 | 518 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 2 | 1997 | 2750 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2018 | 14783 | 0.010 |
Why?
|
| Drug Carriers | 1 | 2006 | 710 | 0.010 |
Why?
|
| Ileum | 1 | 1984 | 558 | 0.010 |
Why?
|
| Comorbidity | 1 | 2016 | 10588 | 0.010 |
Why?
|
| Prisoners | 1 | 2005 | 315 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2012 | 5898 | 0.010 |
Why?
|
| Bile Acids and Salts | 1 | 2004 | 400 | 0.010 |
Why?
|
| Hemodynamics | 1 | 1992 | 4199 | 0.010 |
Why?
|
| Lectins, C-Type | 1 | 2004 | 591 | 0.010 |
Why?
|
| Cloning, Molecular | 2 | 1997 | 4168 | 0.010 |
Why?
|
| Nutritional Status | 1 | 1989 | 1627 | 0.010 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2004 | 567 | 0.010 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2003 | 617 | 0.010 |
Why?
|
| Antigens, Surface | 1 | 2004 | 1616 | 0.010 |
Why?
|
| Epidermal Growth Factor | 1 | 2003 | 698 | 0.010 |
Why?
|
| Intestine, Small | 1 | 1986 | 1218 | 0.010 |
Why?
|
| Diabetes Mellitus | 1 | 2018 | 5890 | 0.010 |
Why?
|
| Th1 Cells | 1 | 2004 | 1042 | 0.010 |
Why?
|
| Th2 Cells | 1 | 2004 | 1078 | 0.010 |
Why?
|
| Antigen Presentation | 1 | 2004 | 1251 | 0.010 |
Why?
|
| TATA Box | 1 | 1998 | 127 | 0.010 |
Why?
|
| Mice, Knockout | 2 | 2004 | 14481 | 0.010 |
Why?
|
| Reactive Oxygen Species | 1 | 2006 | 2146 | 0.010 |
Why?
|
| Viral Structural Proteins | 1 | 1998 | 93 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2006 | 6238 | 0.010 |
Why?
|
| Anti-Retroviral Agents | 1 | 2007 | 1794 | 0.010 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 1985 | 959 | 0.010 |
Why?
|
| Models, Animal | 1 | 2004 | 2124 | 0.010 |
Why?
|
| Chymotrypsin | 1 | 1997 | 137 | 0.010 |
Why?
|
| Feces | 1 | 2004 | 1516 | 0.010 |
Why?
|
| Hepatocytes | 1 | 2004 | 1245 | 0.010 |
Why?
|
| Genomic Library | 1 | 1997 | 188 | 0.010 |
Why?
|
| Sphincterotomy, Endoscopic | 1 | 1996 | 44 | 0.010 |
Why?
|
| Peptide Mapping | 1 | 1997 | 259 | 0.010 |
Why?
|
| Alcoholism | 1 | 1988 | 1981 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2006 | 6084 | 0.010 |
Why?
|
| alpha 1-Antichymotrypsin | 1 | 1996 | 18 | 0.010 |
Why?
|
| Consensus Sequence | 1 | 1997 | 363 | 0.010 |
Why?
|
| Restriction Mapping | 1 | 1997 | 849 | 0.010 |
Why?
|
| Prenatal Diagnosis | 1 | 2004 | 1274 | 0.010 |
Why?
|
| Databases, Factual | 1 | 2012 | 8072 | 0.010 |
Why?
|
| Transfection | 1 | 2004 | 5758 | 0.010 |
Why?
|
| Colorectal Neoplasms | 1 | 1996 | 6969 | 0.010 |
Why?
|
| DNA Damage | 1 | 2006 | 2459 | 0.010 |
Why?
|
| Sepharose | 1 | 1996 | 102 | 0.010 |
Why?
|
| Gene Expression Regulation | 2 | 2004 | 11914 | 0.010 |
Why?
|
| Bacterial Proteins | 1 | 2009 | 3835 | 0.010 |
Why?
|
| Temperature | 1 | 2002 | 2234 | 0.010 |
Why?
|
| Scavenger Receptors, Class B | 1 | 1995 | 85 | 0.010 |
Why?
|
| alpha 1-Antitrypsin | 1 | 1996 | 169 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 1 | 2003 | 3631 | 0.010 |
Why?
|
| Health Services Accessibility | 1 | 2013 | 5511 | 0.010 |
Why?
|
| Receptors, Scavenger | 1 | 1995 | 123 | 0.010 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 1997 | 781 | 0.010 |
Why?
|
| Blotting, Southern | 1 | 1995 | 777 | 0.010 |
Why?
|
| Epitope Mapping | 1 | 1995 | 300 | 0.010 |
Why?
|
| Introns | 1 | 1997 | 968 | 0.010 |
Why?
|
| Sequence Alignment | 1 | 1998 | 2177 | 0.010 |
Why?
|
| DNA Primers | 1 | 1998 | 2823 | 0.010 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 1998 | 827 | 0.010 |
Why?
|
| Rural Population | 1 | 2004 | 2318 | 0.010 |
Why?
|
| Mucous Membrane | 1 | 1997 | 659 | 0.010 |
Why?
|
| Protein Isoforms | 1 | 1998 | 1704 | 0.010 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 1996 | 520 | 0.010 |
Why?
|
| Organ Specificity | 1 | 1998 | 1966 | 0.010 |
Why?
|
| Antibodies, Viral | 1 | 2005 | 3211 | 0.010 |
Why?
|
| Hyperplasia | 1 | 1996 | 1152 | 0.010 |
Why?
|
| von Willebrand Factor | 1 | 1997 | 680 | 0.010 |
Why?
|
| Genes, MHC Class I | 1 | 1993 | 236 | 0.010 |
Why?
|
| Interleukin-8 | 1 | 1995 | 704 | 0.010 |
Why?
|
| Cells, Cultured | 2 | 1998 | 19019 | 0.010 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 1995 | 892 | 0.010 |
Why?
|
| Vaccinia virus | 1 | 1993 | 330 | 0.010 |
Why?
|
| Mutation | 1 | 2016 | 30230 | 0.010 |
Why?
|
| Exons | 1 | 1997 | 2392 | 0.010 |
Why?
|
| Veterans | 1 | 2005 | 2672 | 0.010 |
Why?
|
| Infant | 1 | 2013 | 36512 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 2004 | 4940 | 0.010 |
Why?
|
| Survival Rate | 1 | 2005 | 12870 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2006 | 10464 | 0.010 |
Why?
|
| Pepstatins | 1 | 1989 | 10 | 0.010 |
Why?
|
| Sucralfate | 1 | 1989 | 12 | 0.010 |
Why?
|
| Viral Vaccines | 1 | 1995 | 596 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2013 | 42654 | 0.010 |
Why?
|
| Drug Resistance | 1 | 1996 | 1595 | 0.010 |
Why?
|
| Protein Processing, Post-Translational | 1 | 1998 | 1967 | 0.010 |
Why?
|
| Regional Blood Flow | 1 | 1992 | 1502 | 0.000 |
Why?
|
| Peptic Ulcer | 1 | 1989 | 222 | 0.000 |
Why?
|
| HLA Antigens | 1 | 1993 | 1337 | 0.000 |
Why?
|
| Ireland | 1 | 1988 | 170 | 0.000 |
Why?
|
| Mice, Inbred C57BL | 1 | 2006 | 22355 | 0.000 |
Why?
|
| Anti-Bacterial Agents | 1 | 1986 | 7458 | 0.000 |
Why?
|
| Sequence Analysis, DNA | 1 | 1998 | 4774 | 0.000 |
Why?
|
| Tranexamic Acid | 1 | 1989 | 174 | 0.000 |
Why?
|
| Cell Line, Tumor | 1 | 2003 | 17132 | 0.000 |
Why?
|
| Diet | 1 | 2004 | 8097 | 0.000 |
Why?
|
| Child | 1 | 2013 | 80894 | 0.000 |
Why?
|
| Carcinoembryonic Antigen | 1 | 1985 | 338 | 0.000 |
Why?
|
| Hot Temperature | 1 | 1989 | 1440 | 0.000 |
Why?
|
| Pregnancy | 1 | 2004 | 30198 | 0.000 |
Why?
|
| Brain | 1 | 2002 | 27452 | 0.000 |
Why?
|
| Postoperative Complications | 1 | 1988 | 15854 | 0.000 |
Why?
|